On Sunday, April 20th 2025, starting 8:30am GMT, there will be maintenance work that will involve the website being unavailable during parts of the day. We apologize for any inconvenience this may cause and appreciate your understanding.
We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Cardiovascular disease
- Monogenic form of common disorder
- Single gene disorders and cardiovascular disease
- Genetic basis of the common form of CHD
- Polygenic form of common disorder
- Common forms of cardiovascular disease
- CHD study design
- Candidate genes or whole genome
- Genome wide association studies
- Case and control
- SNPs on chromosome 9 associated with CHD
- A new dawn for genetics of complex disorders
- A new dawn for genetics of complex traits
- Allele frequency and effect size (1)
- Allele frequency and effect size (2)
- Genetic architecture of common disease
- Translation of genomic discoveries
- Genotype knowledge predicting risk of disease
- Potential advantages of genetic tests
- The problem
- Hypothetical population and a perfect test
- A perfect test (cont.)
- A less than perfect test (1)
- A less than perfect test (2)
- A genetic test (1)
- A genetic test (2)
- Rare, high penetrance mut. - population screening
- Rare, high penetrance mut. - family screening
- Another genetic test (1)
- Another genetic test (2)
- Apolipoprotein E as a genetic marker
- Predictive genetic screening for CHD (1)
- Predictive genetic screening for CHD (2)
- Multiple risk alleles
- Genetic profiling perform poorly as a discriminator
- Genotype and prediction of CHD
- Translation of genomic discoveries
- Unique properties of genotype
- Novel biomarkers and cardiovascular disease
- Cardiovascular disease and the translational gap
- Non-causal explanations
- Investigating causal role through experimentation
- Non-experimental studies in humans
- "The cholesterol myth"
- Identification and validation of a "drug-target"
- The final arbiter of the validity - RCT in humans
- Observational studies and RCTs of statin drugs
- Attrition of new molecular entities
- "Nature's randomised trials"
- Homocysteine and stroke
- Possible explanations of this observation
- Difference in Hcy according to genotypes
- Random allocation of MTHFR genotypes
- Genotype, risk marker and event rate (1)
- Genotype, risk marker and event rate (2)
- Observed genetic effect and observational studies
- LDL-C and CHD: Mendelian randomisation study
- Mendelian randomisation: a historical perspective
- Conclusion
Topics Covered
- Ischaemic heart disease
- Valvular heart disease
- Heart muscle disease
- Monogenic form of common disorder
- Single gene disorders and cardiovascular disease
- Mutation both necessary and sufficient to lead to disease
- Genetic basis of the common form of CHD
- Polygenic form of common disorder
- Complex disorders
- Study design
- Candidate genes or whole genome
- Genome-wide association studies
- A new dawn for genetics of complex disorders and traits
- Relationship between allele frequency and effect size
- Genetic architecture of common disease
- Translation of genomic discoveries
- Potential advantages of genetic tests
- Predictive genetic screening for CHD
- Low penetrance polymorphisms
- Multiple risk alleles
- Why genetic testing might perform poorly as a discriminatory test
- Genotype and prediction of CHD
- Using genotype to gain insight into the causes of CHD
- Unique properties of genotype
- Novel biomarkers and CVD
- CVD and the translational gap
- Attrition of new molecular entities
- Association of a quantitative trait with clinical events may have a non-causal explanation
- Investigating causal role through experimentation
- Validation of a drug target requires experimentation
- Non-experimental studies in humans
- The "cholesterol myth"
- Identification and validation of a "drug-target"
- The final arbiter of the validity of the therapeutic target is the RCT in humans
- Nature's randomized trials
- Homocysteine and stroke
- Triangulation between genotype, biochemical risk marker and event rate
- Mendelian randomization
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Hingorani, A. (2008, December 18). Translational applications of cardiovascular genomics: opportunities and challenges [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 15, 2025, from https://doi.org/10.69645/GAID3730.Export Citation (RIS)
Publication History
- Published on December 18, 2008
Financial Disclosures
- Dr. Aroon Hingorani has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Hide